Insider Selling: Pharvaris (NASDAQ:PHVS) CFO Sells $303,100.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CFO David Nassif sold 10,000 shares of Pharvaris stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.31, for a total transaction of $303,100.00. Following the sale, the chief financial officer directly owned 120,300 shares of the company’s stock, valued at approximately $3,646,293. This trade represents a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Pharvaris Trading Up 1.3%

Pharvaris stock opened at $29.86 on Friday. The stock has a market cap of $1.95 billion, a P/E ratio of -9.39 and a beta of -2.34. The company has a fifty day simple moving average of $28.72 and a 200-day simple moving average of $27.07. Pharvaris N.V. has a 12-month low of $15.51 and a 12-month high of $33.33.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi boosted its position in shares of Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PHVS shares. Royal Bank Of Canada decreased their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Citizens Jmp lowered their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. UBS Group set a $74.00 target price on shares of Pharvaris in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Finally, Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.